
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Corbus Pharmaceuticals Holdings, Inc.

(Name of Issuer)

Common Stock, par value, \$0.0001 per share
(Title of Class of Securities)

21833P103
(CUSIP Number)

October 25, 2022
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

Continued on following pages

Page 1 of 9 Pages

Exhibit Index: Page 8

1	NAMES OF REPORTING PERSONS K2 HealthVentures Equity Trust LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 10,524,401 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 10,524,401 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,524,401 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% ⁽¹⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

⁽¹⁾ See Items 2 and 4

1	NAMES OF REPORTING PERSONS Parag Shah	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 10,524,401 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 10,524,401 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,524,401 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% ⁽¹⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC, IN	

⁽¹⁾ See Items 2 and 4

1	NAMES OF REPORTING PERSONS Anup Arora	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 10,524,401 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 10,524,401 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,524,401 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.8% ⁽¹⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC, IN	

⁽¹⁾ See Items 2 and 4

Item 1(a). Name of Issuer:

Corbus Pharmaceuticals Holdings, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

500 River Ridge Drive, Norwood, MA 02062

Item 2(a). Name of Person Filing:

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i. K2 HealthVentures Equity Trust LLC ("K2HV Equity");
- ii. Parag Shah ("Mr. Shah"); and
- iii. Anup Arora ("Mr. Arora").

This Statement on Schedule 13G relates to shares of Common Stock (as defined herein) that the Reporting Persons have the right to acquire within 60 days upon (i) exercise of warrants to purchase 86,206 shares of Common Stock at an exercise price of \$6.96 per share, which warrants expire on July 28, 2030 (the "Warrants"), directly held by K2HV Equity, and (ii) conversion of up to \$5,000,000 of the remaining balance of the Issuer's outstanding debt obligations to K2 HealthVentures LLC under the Loan and Security Agreement, dated as of July 28, 2020, as amended by the Amended Loan Agreement, dated as of October 25, 2022 (together, the "Loan Agreement") into 10,438,195 shares of Common Stock directly held by K2HV Equity (the "Conversion Shares"). Pursuant to the terms of the Warrant and the Loan Agreement, the Reporting Persons may not exercise any portion of the Warrant, or convert any portion of the Conversion Shares, into shares of Common Stock to the extent that, upon exercise or conversion, the beneficial ownership of the Reporting Persons (including any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the Reporting Persons' beneficial ownership for purposes of Section 13(d) of the Act) would exceed 9.985% of the total number of shares of Common Stock outstanding (the "9.985% Cap").

K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon exercise of the Warrants and conversion of the Conversion Shares, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns.

Item 2(b). Address of Principal Business Office or, if none, Residence:

The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.

Item 2(c). Citizenship:

K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.

Item 2(d). Titles of Classes of Securities:

Common Stock, par value \$0.0001 per share ("Common Stock")

Item 2(e). CUSIP Number:

21833P103

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

This Item 3 is not applicable.

Item 4. Ownership:Item 4(a). Amount Beneficially Owned:

As of October 25, 2022, each of the Reporting Persons may be deemed the beneficial owner of 10,524,401 shares of Common Stock that K2HV Equity has the right to acquire within 60 days upon exercise of the Warrants and conversion of the Conversion Shares, subject to the 9.985% Cap.

Item 4(b). Percent of Class:

As of October 25, 2022, each of the Reporting Persons may be deemed the beneficial owner of approximately 7.8% of the shares of Common Stock outstanding.

The percentages set forth herein are calculated based on the sum of: (i) 125,268,381 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 9, 2022, and (ii) 10,524,401 shares of Common Stock that are issuable to the Reporting Persons within 60 days upon exercise of the Warrants and conversion of the Conversion Shares, subject to the 9.985% Cap, which shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

Item 4(c). Number of Shares as to which such person has:K2HV Equity, Mr. Shah and Mr. Arora

(i) Sole power to vote or direct the vote:	0
(ii) Shared power to vote or direct the vote:	10,524,401
(iii) Sole power to dispose or direct the disposition of:	0
(iv) Shared power to dispose or direct the disposition of:	10,524,401

Item 5. Ownership of Five Percent or Less of a Class.

This Item 5 is not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

This Item 6 is not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

This Item 7 is not applicable.

Item 8. Identification and Classification of Members of the Group.

This Item 8 is not applicable.

Item 9. Notice of Dissolution of Group.

This Item 9 is not applicable.

Item 10. Certification. (if filing pursuant to Rule 13d-1(c))

By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

K2 HEALTHVENTURES EQUITY TRUST LLC

By: /s/ Anup Arora

Name: Anup Arora

Title: Managing Member

PARAG SHAH

By: /s/ Parag Shah

ANUP ARORA

By: /s/ Anup Arora

EXHIBIT INDEX

Exhibit

Page No.

A – Joint Filing Agreement

9

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Corbus Pharmaceuticals Holdings, Inc., dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 14, 2024

K2 HEALTHVENTURES EQUITY TRUST LLC

By: /s/ Anup Arora

Name: Anup Arora

Title: Managing Member

PARAG SHAH

By: /s/ Parag Shah

ANUP ARORA

By: /s/ Anup Arora
